Clinical Trial Update: A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 trial evaluating safety and efficacy of ruxolitinib in myelomonocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelomonocytic Leukemia

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Myelomonocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-12